Xin Yao

Dr. Xin Yao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
XYXin Yao
Xin Yao
RHRodger F. Henry
Rodger F. Henry
GZGeoff G.Z. Zhang
Geoff G.Z. Zhang

23 June 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XYXin Yao
Xin Yao
QLQitong Liu
Qitong Liu
Bu WangBu Wang
Bu Wang
JYJunguang Yu
Junguang Yu
MAMichael M. Aristov
Michael M. Aristov
LYLian Yu
Lian Yu

8 September 2020 in Chemistry of Materials
Verified
Journal Article
Closed access
YGYue Gui
Yue Gui
XYXin Yao
Xin Yao
IGIlia A. Guzei
Ilia A. Guzei
MAMichael M. Aristov
Michael M. Aristov
JYJunguang Yu
Junguang Yu
LYLian Yu
Lian Yu

1 February 2021 in Molecular Pharmaceutics
Verified
Journal Article
Open access
YGYue Gui
Yue Gui
EMErin C. McCann
Erin C. McCann
XYXin Yao
Xin Yao
YLYuhui Li
Yuhui Li
KJKaren J. Jones
Karen J. Jones
LYLian Yu
Lian Yu
We report that the stability of amorphous clofazimine (CFZ) against crystallization is vastly improved by salt formation with a polymer without sacrificing dissolution rate. A simple slurry method was used to produce the amorphous salt of CFZ with poly(acrylic acid) (PAA) at 75 wt % drug loading. The synthesis was performed under a mild condition suitable for thermally unstable drugs and polymers. Salt formation was confirmed by visible spectroscopy and glass temperature elevation. The amorphous salt at 75 wt % drug loading is remarkably stable against crystallization at 40 °C and 75% RH for at least 180 days. In contrast, the amorphous solid dispersion containing the un-ionized CFZ dispersed in poly(vinylpyrrolidone) crystallized in 1 week under the same condition. The high stability of the amorphous drug–polymer salt is a result of the absence of a drug–polymer crystalline structure, reduced driving force for crystallizing the free base, and reduced molecular mobility. Despite the elevated stability, the amorphous drug–polymer salt showed fast dissolution and high solution concentration in two biorelevant media (SGF and FaSSIF). Additionally, the amorphous CFZ–PAA salt has improved tabletability and powder flow relative to crystalline CFZ. The CFZ–PAA example suggests a general method to prepare amorphous drugs with high physical stability under tropical conditions and fast dissolution.

15 November 2019 in Crystal Growth & Design
Verified
Journal Article
Closed access
XYXin Yao
Xin Yao
CHChengbin Huang
Chengbin Huang
EBEmily G. Benson
Emily G. Benson
CSChenyang Shi
Chenyang Shi
GZGeoff G. Z. Zhang
Geoff G. Z. Zhang
LYLian Yu
Lian Yu

28 April 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XYXin Yao
Xin Yao
EBEmily G. Benson
Emily G. Benson
YGYue Gui
Yue Gui
Torsten StelzerTorsten Stelzer
Torsten Stelzer
GZGeoff G. Z. Zhang
Geoff G. Z. Zhang
LYLian Yu
Lian Yu